QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Primary End Point:
- To compare the overall survival (OS) using QYHJ Granules or Xeloda as the second therapy in
patients with metastatic pancreatic cancer.
Secondary End Points:
- Compare clinical efficacy by other measures including PFS,tumor response,and changes in
quality of life (QOL) between these two groups.
- Examine the feasibility and assess the side effects of treatment using QYHJ Granules in
patients with metastatic pancreatic cancer.